This Senate resolution formally expresses support for designating September 2026 as "Sickle Cell Disease Awareness Month" to raise public understanding of the inherited blood disorder, which affects an estimated 100,000 Americans and disproportionately impacts Black and Hispanic communities. The resolution highlights serious health consequences of sickle cell disease, including strokes, organ damage, chronic pain, and significantly shortened life expectancy, while noting gaps in recommended screenings and treatments for affected children. It also points to recent medical progress, such as the FDA's approval of two gene therapies (Casgevy and Lyfgenia) and an expanded 2026 approval for Casgevy, as well as a Medicare and Medicaid program supporting access to these treatments in most states. The resolution does not create new funding or programs but encourages Americans to hold events and activities during the month to promote awareness of sickle cell trait, prevention, and treatment options. As a symbolic measure, it carries no binding legal requirements or timelines beyond the designated awareness month itself.